|1.||Jacobi, Christoph A: 10 articles (01/2009 - 01/2003)|
|2.||Braumann, Chris: 10 articles (01/2009 - 01/2003)|
|3.||Braumann, C: 7 articles (12/2012 - 01/2000)|
|4.||Menenakos, Charalambos: 7 articles (01/2009 - 01/2005)|
|5.||Möhler, Hanns: 5 articles (10/2014 - 05/2003)|
|6.||Daigeler, Adrien: 5 articles (11/2010 - 01/2008)|
|7.||Uhl, Waldemar: 5 articles (01/2010 - 09/2007)|
|8.||Mittelkötter, Ulrich: 5 articles (01/2010 - 09/2007)|
|9.||Jacobi, C A: 5 articles (01/2007 - 01/2000)|
|10.||Stendel, Ruediger: 5 articles (01/2007 - 03/2002)|
03/01/2015 - "The study did not observe any additional clinical value of taurolidine in patients receiving HPN who have a low infection rate and found low cost-effectiveness. "
03/01/2015 - "Therefore, the aim of this study was to analyze the clinical value of taurolidine in patients receiving HPN who have a low infection rate. "
08/01/2009 - "Based on a prospective, unicentre observational study on the implantation of an i. v. port-a-cath (daily surgical practice) enrolling consecutive patients of a representative number and through a defined study period (design, case series), besides patient and intervention-associated characteristics, we investigated 1. the spectrum of causes for an i. v. port-a-cath explantation; 2. the option of a conservative i. v. port-a-cath-maintaining, endoluminal, antiseptic local therapy in a selected number of patients with microbiologically detected infection of the i. v. port-a-cath using 2 x 5.0 ml taurolin 2.0 % / d for 3 d as an accompanying clinical observation of initial therapeutic use and its effect. "
10/01/2013 - "Infection rates after commencing taurolidine decreased markedly in all patients studied. "
10/01/2012 - "A total of 14 of the 19 patients (74%) had no infections for up to 33 months after changing to taurolidine. "
01/01/2006 - "The intravenous treatment with 2% taurolidine led to a histological remission of the tumor growth without any toxicity for the patient."
02/01/2002 - "Exposure of these chimeric cultures to 5 mM Taurolidine for 1 h totally eliminated viable cancer cells while minimally reducing viable BM cells. "
04/01/2010 - "Such randomized control studies are vital to clarify the role of taurolidine in modern cancer treatment."
01/01/2009 - "The aim of this study was to determine whether an intravenous or an intraperitoneal application of the antineoplastic agent taurolidine (TRD) impairs wound healing in the absence of tumor load in rats. "
02/01/2005 - "The object of this study was to examine the effect of taurolidine on intraabdominal tumor growth in a laparoscopic animal model. "
01/01/2011 - "It remains undetermined if, with different doses and methodology, taurolidine could be more effective in treating bacterial and/or fungal peritonitis. "
01/01/2006 - "The reported antibacterial, antiendotoxic, and antiadhesive effects of taurolidine prompted us to study the benefits of intraperitoneal lavage with taurolidine on primary colonic anastomosis in a rat model of secondary peritonitis. "
01/01/2002 - "The aim of this study was to evaluate the influence of taurolidine (TAU) and polyhexanid (POLY) on basic inflammatory reactions during peritonitis by using an in vitro model of human peritoneum. "
05/01/1978 - "C controlled trial of taurolin in established bacterial peritonitis."
01/01/2006 - "Intraperitoneal lavage with taurolidine solution may reduce the risks associated with performing primary colonic anastomosis in patients with secondary peritonitis."
08/01/2008 - "To review available literature and examine the evidence for efficacy of taurolidine in prevention of central venous catheter-related infection. "
04/01/2014 - "This study was designed to present our experiences of the TIAPs applications and efficacy of Taurolidine-citrate lock solution (TCLS) against catheter-related infections. "
04/01/2014 - "Complications of total implantable access ports and efficacy of Taurolidine-citrate lock solution against catheter-related infections."
06/01/2002 - "These findings suggest that taurolidine-citrate is a promising combination agent for the prevention and treatment of intravascular catheter-related infections."
01/14/2008 - "Taurolidine is an antimicrobial agent used to prevent intraabdominal adhesion formation and sepsis in experimental and clinical trials. "
01/01/1988 - "Clinical studies on administration of taurolin in severe sepsis: a preliminary study."
04/01/2013 - "We further evaluated the immunomodulatory role of the amino-acid derivative taurolidine in our in vitro sepsis model. "
06/01/2004 - "This study shows that catheter filling with a solution containing the antimicrobial taurolidine may significantly reduce the incidence of catheter-related sepsis. "
08/01/2008 - "Taurolock (Bio-Implant HealthCare, Winsen, Germany), which contains taurolidine, is being marketed as a central venous catheter lock solution for decreasing the risk of catheter sepsis. "
|2.||Citric Acid (Citrate)
|3.||Anti-Bacterial Agents (Antibiotics)
|8.||Eosine Yellowish-(YS) (Eosin)
|2.||Home Parenteral Nutrition
|4.||Intensive Care (Surgical Intensive Care)